Chris Garabedian on the "middle market" of biotech VC.

Ep23: Chris Garabedian

"The Long Run"

Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. 

Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.

Science

"The Long Run" Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.

Share Ep23: Chris Garabedian

Sign up to save your podcasts

Ep23: Chris Garabedian

Ep23: Chris Garabedian

More shows like The Long Run with Luke Timmerman

Nature Podcast

Freakonomics Radio

POP | TECH | JAM

About Men Radio

Strings and Things

The Workup

Up First from NPR

KFF Health News' 'What the Health?'

The Readout Loud

The Journal.

Biotech 2050 Podcast

Business Of Biotech

BioCentury This Week

Raising Health

The Ezra Klein Show

Biotech Hangout

NEJM AI Grand Rounds

Ground Truths

The BioCentury Show